Matthias Staehelin

Institut Straumann AG operates a dentistry group. It engages in the research, development and manufacturing dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions. The company is headquartered in Basel, Switzerland.

Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.

Clinerion AG develops software and solutions for pharmacovigilance. It provides consulting and outsourcing services for pharmaceutical industry and non-governmental organizations. The firm offers its own client-tailored software solutions for improvement of quality, compliance & performance of clinical trials operations. The company was founded in 2008 and is headquartered in Basel, Switzerland.

Jungbunzlauer Holding AG operates a holding company with interest in biodegradable ingredients such as citric acids and salts. It operates through its subsidiary Jungbunzlauer AG. The company was founded on December 17, 1970 and is headquartered in Chur, Switzerland.

Parkresort Rheinfelden Holding AG operates a health resort in Switzerland. Its facilities include Park-Hotel am Rhein, a hotel that provides rooms, spa treatments, restaurants, banquets, seminar facilities, and residence- apartments, sole uno wellness world, which offer water parks, saunas, and massage lounges. The firm also provides rehabilitation clinics, medical specialists, and therapies for the prevention, diagnosis, and treatment of the musculoskeletal system. The company was founded on January 13, 1970 and is headquartered in Rheinfelden, Switzerland.

Nordic Cultural & Educational Foundation engages in the holding and management of investments. Investment contributions and other profits made by the Foundation are used to provide training and research grants. It also offers and organizes educational and work contributions to artists in the fields of visual arts, music, and literature. The company was founded on December 27, 2005 and is headquartered in Basel, Switzerland.

Anchor 3PL, LLC is a warehousing and logistics company that offers a range of services including raw and finished food-grade inventory, dry goods, retail fulfillment, and routing guide solutions. The company is based in Salt Lake City, UT. The CEO of the company is Sam Souvall.

persona service AG & Co. KG engages in the provision of temporary employment and human resource services. It offers staff leasing, personnel placement, human resources consultation, onsite and project management, and customer support services. The company was founded in 1967 and is headquartered in Luedenscheid, Germany.

Part of Dolder Bigler AG, Dolder AG is a Swiss company that specializes in producing high-quality plastics and specialty chemicals. The company is based in Basel, Switzerland and works with other industry leaders such as Coim, Eastman, Evonik, and Huntsman to provide top-of-the-line products for their customers. The company's laripur® tpu and ™ copolyester products are used for injection molding and extrusion, and offer a soft touch effect and higher heat and chemical resistance than other materials.

Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million.

ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.